Trial Information

Summary: A 24-month, double-blind, randomized, multi-center, placebo-controlled, parallel-group study comparing the efficacy and safety of FTY720 1.25mg and 0.5mg administered once daily versus placebo in patients with relapsing remitting multiple sclerosis

This purpose of this clinical research study to find out if an oral once-a-day investigational drug called FTY720 is safe and has beneficial effects in people who have Multiple Sclerosis (MS). The study will evaluate how effective the study drug is in reducing the number of relapses in patients with relapsing-remitting MS treated for up to 2 years. It will also evaluate how safe and well tolerated the study drug is when used for up to 2 years.

No Compensation Provided

Patient Inclusion/Exclusion Criteria:

- Men and women, 18-55 years of age
- A diagnosis of relapsing remitting MS (RRMS)
- At least 1 physician documented relapse during the previous year or 2 physician documented relapses in the past 2 years
- Patients who decline initiation or cont

- Women who are pregnant or breastfeeding
- History of diabetes, heart, lung or liver disease
- History of study drug (fingolimod/FTY720) use
- Other medical conditions and drug therapies that will be assessed at the screening visit
- Partici

If you would like to learn more about participating in this study, please send an e-mail message using the form below.